| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-26 | Asahi Kasei Pharma (Japan) Evotec (Germany) | inhibitors of multiple ion channel targets | undisclosed | services contract |
undisclosed | Services contract |
| 2015-03-26 | Orion (Finland) HUCH Comprehensive Cancer Center (Finland) | collaboration clinical research development |
Cancer - Oncology | Collaboration agreement | ||
| 2015-03-26 | Oncodesign (France) Synthon Biopharmaceuticals (The Netherlands) | antibody-drug conjugates (ADCs), for multiple oncology targets | R&D collaboration |
Cancer - Oncology - Technology - Services | R&D agreement | |
| 2015-03-26 | Stada (Germany) Hetero Labs (India) | joint-venture agreement |
Joint-venture agreement | |||
| 2015-03-25 | AstraZeneca (UK) Harvard Stem Cell Institute (USA - MA) | human beta cells | diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2015-03-25 | Cytos Biotechnology (Switzerland) Novartis (Switzerland) | CAD 106 | Alzheimer\'s disease | product acquisition |
Neurodegenerative diseases | Product acquisition |
| 2015-03-25 | Genvec (USA - MD) TheraBiologics (USA - CA) | TBX02 | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-03-24 | Institut Pasteur (France) Integragen (France) | highthroughput sequencing activities in microbiology | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-03-24 | BMS (USA - NY) Novo Nordisk (Denmark) | undisclosed discovery biologics research program focused on modulating the innate immune system | autoimmune diseases | licensing |
Autoimmune diseases | Licensing agreement |
| 2015-03-24 | Emergent BioSolutions (USA - MD) Biomedical Advanced Research and Development Authority (BARDA) (USA) | NuThrax® | anthrax | services contract |
Infectious diseases | Services contract |
| 2015-03-23 | Cardio3 Biosciences (Belgium) | manufacturing facility in Rochester | opening of new premises | Cardiovascular diseases - Cancer - Oncology | Opening of new premises | |
| 2015-03-23 | Teva Pharmaceutical Industries (Israel) | nomination |
Nomination | |||
| 2015-03-23 | Immunogen (USA - MA) Millennium Pharmaceuticals (USA - MA) Takeda Pharmaceutical (Japan) | Antibody drug conjugate (ADC) technology | licensing |
Technology - Services - Cancer - Oncology | Licensing agreement | |
| 2015-03-23 | Neovacs (France) | establishment of a new subsidiary in the US |
Autoimmune diseases | Establishment of a new subsidiary in the US | ||
| 2015-03-23 | Foundation Medicine (USA -MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-23 | Foundation Medicine (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-03-23 | Cortendo (Sweden) | nomination |
Rare diseases - Hormonal diseases - Endocrine diseases | Nomination | ||
| 2015-03-23 | Horizon Discovery (UK) ArcherDX (USA - CO) | Horizon’s reference materials | distribution |
Technology - Services | Distribution agreement | |
| 2015-03-23 | Blueprint Medicines (USA - MA) | nomination |
Cancer - Oncology - Genetic diseases | Nomination | ||
| 2015-03-23 | AOP Orphan Pharmaceuticals (Austria) Confluence Pharmaceuticals | acamprosate | fragile X syndrome | development |
Rare diseases - Genetic diseases | Development agreement |
